13F-HR filed Aug 13, 2026 at 14:51 ET
Morgan Stanley's Q2 2026 13F filing reveals a portfolio with a total value of approximately $1.89 trillion, filed shortly after the company reported record quarterly results. The filing shows significant new positions in AbSci Corporation, Eos Energy Enterprises, and Harmony Biosciences, alongside substantial increases in existing positions like Rhythm Pharmaceuticals and Standard Lithium. The portfolio also reflects a rotation into energy and materials sectors, with notable increases in Canadian Natural Resources and Permian Resources, while reducing exposure to some financial and tech names. The filing is consistent with the firm's strong earnings report, which saw record net revenues of $21.3B and a $20B buyback authorization, suggesting a confident deployment of capital into growth and thematic areas.